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synthesized and evaluated for cytotoxic activity against a leukemia cell line and a small panel of human-tumor cell lines. Those
compounds containing a cyclopentenone moiety were active, with the carbonyl group being essential for biological activity.
# 2003 Elsevier Science Ltd. All rights reserved.Neocarzinostatin (NCS), an antitumour antibiotic iso-
lated from Streptomyces carzinostaticus, has found clin-
ical application in Japan against leukemia and cancers
of the bladder, stomach, pancreas, liver and brain.1,2
NCS comprises a highly reactive enediyne chromophore
(1) non-covalently bound to an 11 kDa protein
(apoNCS). The cytotoxic activity of NCS results from
cycloaromatization of the 9-membered enediyne ring of
1,3 which produces a di-radical species that targets
DNA. Minor-groove binding and intercalation of the
naphthoate moiety (2) position the di-radical species
such that hydrogen abstraction occurs from the deoxy-
ribose sugar backbone, which leads to single and double
stranded cleavage.4
Significant practical difficulties are associated with the
design of analogues of 1. NCS chromophore is difficult
to synthesize and handle; hence analogues incorporating
the 9-membered enediyne are potentially also hard to
prepare and manipulate. Because of such difficulties we
propose that the naphthoate portion of 1 could be used
as a synthetic base for the design of new cytotoxic enti-
ties that would be simpler to prepare and more stablethan enediyne containing analogues of 1.5 Here we
report a new class of analogues of NCS that retain a
naphthoate component, but are devoid of the enediyne
motif. Our findings indicate that simple cyclopentenone
derivatives incorporating a naphthoate moiety exhibit
significant cytotoxic activity against cultured human cell
lines. The results obtained for 5a, 5b and 5c compare
favourably with the activity shown for the clinically
used anti-cancer drug Melphalan.
Dicyclohexyl carbodiimide (DCC) coupling was used to
prepare a series of esters incorporating either the NCS
naphthoate 2 or the readily available 2-hydroxy-naph-0960-894X/03/$ - see front matter # 2003 Elsevier Science Ltd. All rights reserved.
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thoic acid (3) from 4a or 4b, (Scheme 1).69 Protecting-
group manipulation afforded both regio-isomers, whilst
Luche-type reduction of the conjugated carbonyl group
afforded an analogous set of dihydroxy cyclopentenes.
The latter, which lack the enone functionality, are poor
electrophiles/alkylators and are anticipated to show
negligible cytotoxic action. A subset of compounds was
also made with bromine alpha to the carbonyl, increas-
ing the electrophilicity of the cyclopentenones and hence
their potential activity.
All compounds were tested for in vitro cytotoxic activity
against the human leukemic cell line K562 (Table 1).10
As anticipated, dihydroxylated cyclopentenes were
found to be inactive at the concentrations used. The
cyclopentenones showed activity at micro-molar con-
centrations, demonstrating that the carbonyl group was
required for cytotoxic activity. However, the presence of
bromine alpha to the carbonyl had little affect on the
potency of these compounds. Otherwise, no significant
structure–activity trend was seen for the regioisomers,
or the identity of the naphthoate moiety with this cell
line.
The active compounds were then screened against a
small panel of human-tumor cell lines {A2780,
A2780CisR, CH1, SKOV-3 (ovarian) and HT29
(colon)}, (Table 2).11 Differences in the activity of com-
pounds not previously apparent were noted in thisscreen. Firstly, the brominated compounds 5c and 8c
were found to be less active than the simple enones 5b
and 8b respectively. Secondly the 40 regioisomers 8a–b
were more active than the 50 regio-isomers 5a–b, most
noticeably when the aromatic substituent was 2. Inter-
estingly, comparison of the potency of analogues
against the cell lines A2780 and A2780CisR, the latter
possessing 15-fold resistance to cisplatin, showed that
the level of resistance was reduced, and in some cases
almost completely circumvented (e.g., 5a, 5c, 8a). The
potency of the compounds also varied between different
cell lines, suggesting that structural features of the
compounds have the potential to discriminate between
cell types.
In conclusion, we have demonstrated that simple
naphthoate-derived analogues of NCS chromophore,
which contain a cyclopentenone, possess cytotoxic
activity in the micro-molar range against a leukemia cell
line and a small panel of human-tumor cells. These data
demonstrate that this type of NCS chromophore analo-
gue has sufficient potency to be of potential therapeutic
interest. Such species offer considerable advantages, as
they are easy to prepare and handle. Studies directed
towards determining the mode of biological action of
these analogues are underway.Acknowledgements
We are grateful to Cancer Research UK, EPSRC,
BBSRC, AICR, AstraZeneca, GlaxoSmithKline,
Novartis and the Centre for Biomolecular Design and
Drug Development at the University of Sussex for sup-
porting our programme.References and Notes
1. Ishida, N.; Miyuzaki, K.; Kumagai, K.; Rikimaru, M. J.
Antibiot. 1965, 18, 68.
2. Maeda, H.; Edo, K.; Ishida, N. In Neocarzinostatin: The
Past, Present and Future of an Anticancer Drug; Springer-Ver-
lag: Tokoyo, 1997, p 287.
3. Myers, A. G. Tetrahedron Lett. 1987, 28, 4493.
4. Gao, X.; Stassinopoulos, A.; Rice, J. S.; Goldberg, I. H.
Biochemistry 1995, 34, 40.
5. Hodgkinson, T. J.; Kelland, L. R.; Shipman, M.; Suzenet,
F. Bioorg. Med. Chem. Lett. 2000, 10, 239.
6. Caddick, S.; Khan, S. J. Chem. Soc., Chem. Comm. 1995,
19, 1971.Scheme 1. Synthesis of naphthoate esters. (a) DCC, ArCO2H, THF/
DCM 1:1, 0 C; (b) CeCl3.7H2O, NaBH4, CH2Cl2, 0 C; (c) TiCl4,
CH2Cl2, 0
C; (d) tert-Butyl-ammonium fluoride, CH2Cl2, 0 C.Table 1. Cytotoxicity of compounds against leukemic cell line K562Compd Cytotoxicity Compd Cytotoxicity
IC50, mMa IC50, mMa5a 4.51.5 8a 5.01.0
5b 4.02.0 8b 6.01.0
5c 5.02.0 8c 3.52.5
6a >100 9a >100
6b >100 9b >100
Melphalan 304
a1 h Incubation. Values are means of three experiments, standard
deviation is given.Table 2. Cytotoxicity of compounds against a small cell line panelCompd Cytotoxic activitya againstA2780 A2780CisR CH1 SKOV-3 HT295a 9.4 9.0 11.0 7.2 13.0
5b 3.7 9.4 5.8 3.1 12.0
5c 9.4 13.0 11.0 9.4 >25
8a 2.5 4.0 2.5 2.5 11.0
8b 2.7 8.6 4.0 2.3 12.0
8c 10.0 17.5 11.0 11.0 >25a96 h Incubation, IC50 (mM) values.2026 M. D. Urbaniak et al. / Bioorg. Med. Chem. Lett. 13 (2003) 2025–2027
7. Caddick, S.; Khan, S.; Frost, L. M.; Smith, N. J.; Cheung,
S.; Pairaudeau, G. Tetrahedron 2000, 56, 8953.
8. Caddick, S.; Cheung, S.; Doyle, V. E.; Frost, L. M.; Soscia,
M. G.; Delisser, V. M.; Williams, M. R.; Etheridge, Z. C.;
Khan, S.; Hitchcock, P. B.; Pairaudeu, G.; Vile, S. Tetra-
hedron 2001, 57, 6295.
9. Urbaniak, M. D.; Muskett, F. W.; Finucane, M. D.; Cad-
dick, S.; Woolfson, D. N. Biochemistry 2002, 41, 11731.
10. Cytotoxicity assay: 200 mL of K562 cells (5  104 cells/mL)
were aliquoted into 96-well microtitre plate and incubated for
1 h with the test compound (100 mM to 30 nM). After washing,
the cells were incubated for a further four days before the
number of viable cells was counted using the MTT assay. Fora description of the MTT assay see: Alloy, M. C.; Scudiero,
D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine,
D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd,
M. R. Cancer Res. 1988, 48, 589.
11. Cytotoxicity assay: Cells were added to 96-well micro-
titre plates (5  104 cells/mL) and allowed to attach over-
night. Test compounds (100mM to 2.5 nM) were incubated
with the cells for 96 h, then the number of cells was coun-
ted using the Sulforhodamine B (SRB) assay. For a
description of the SRB assay see: Skehan, P.; Storeng, R.;
Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren,
J.; Bokesh, H.; Kennedy, S.; Boyd, M. R. J. Nat. Cancer Inst.
1990, 82, 1107.M. D. Urbaniak et al. / Bioorg. Med. Chem. Lett. 13 (2003) 2025–2027 2027
